Atara Biotherapeutics Inc (NAS:ATRA)
$ 10.28 -1.35 (-11.61%) Market Cap: 58.33 Mil Enterprise Value: 83.40 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 40/100

Atara Biotherapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript

Dec 02, 2020 / 01:50PM GMT
Release Date Price: $592.5 (+1.28%)
Jonathan Miller
Evercore ISI - Analyst

Hello everybody. And welcome to our Fireside with Atara. Mike and I are hosting management, we have Pascal and Jakob here with us today. We're so happy to have you here to answer our questions, so welcome. Pascal, why don't you to lead us off. I understand you've got a few introductory remarks.

Pascal Touchon
Atara Biotherapeutics, Inc. - President and Chief Executive Officer

Yes. Good morning all. Pleasure to be with you. Atara Biotherapeutics is truly a leader in off-the-shelf Allogeneic T-cell Immunotherapy with five key unique features.

First we have a differentiated Allogeneic Cell Therapy Platform which is scalable, we know how to make this allogeneic cell in terms of thousands of patients not only a few hundred of patients, and tens of thousands of patients as well.

It's also flexible in the sense that we can make different types of allogeneic T cell therapies, so differentiated allogeneic cell therapy platform.

We're also the first-in-kind late-stage oncology asset Tab-cel with BTD,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot